NEW YORK (GenomeWeb News) – Goldman Sachs on Monday upgraded shares of Danaher's stock, while it downgraded Waters' shares.

Analyst Isaac Ro upgraded Danaher to a Buy rating from a prior rating of Neutral and raised the 12-month price target on the company's stock to $88 from $75. He also downgraded Waters to a Neutral rating from Buy, and reduced the price target on its stock to $107 from $117.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.